Document Detail


Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma.
MedLine Citation:
PMID:  17604664     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To investigate the relative efficacy of ciclesonide and fluticasone propionate (FP) administered at comparable microgram doses in maintaining asthma control in patients with moderate-to-severe persistent asthma.
METHODS: This randomized, open-label, parallel-group study enrolled patients aged 12-75 years with a 6-month history of bronchial asthma. To enter a 2-week run-in period, patients had to have received FP 500-1000 microg/day or equivalent at a stable dose for 4 weeks and have a forced expiratory volume in 1s (FEV 1) 80% of predicted. To enter the treatment period, patients had to have the following during run-in: FEV 1 80% of predicted; reversibility of Delta FEV 1 12% after 200-400 microg salbutamol; and 1 day without asthma symptoms during the last 7 days. Patients were randomized to twice-daily ciclesonide 320 microg (ex-actuator) or twice-daily FP 330 microg (ex-actuator) for 6 months. Efficacy was assessed by lung function, asthma exacerbations, asthma symptoms and rescue medication use. Patients completed the standardized version of the Asthma Quality of Life Questionnaire (AQLQ[S]). Adverse events (AEs), including local oropharyngeal AEs, were recorded.
RESULTS: 528 patients were randomized (ciclesonide, n=255; FP, n=273). In both groups, FEV 1 was maintained from baseline to study end (mean increase: ciclesonide 11 mL, FP 24 mL; intention-to-treat [ITT] analysis). The least squares mean+/-standard error of the mean for the treatment difference was -13+/-29 (95% confidence interval [CI]: -70, 44) in the ITT analysis and -27+/-34 (95% CI: -93, 40) in the per-protocol (PP) analysis, demonstrating non-inferiority of ciclesonide to FP. Morning, evening and site-measured PEF improved significantly with both treatments (ITT and PP analyses: p<0.05). Six patients receiving ciclesonide and seven receiving FP (ITT analysis) experienced an asthma exacerbation requiring treatment with oral corticosteroids. Both treatments significantly decreased asthma symptom score sum (ITT and PP analyses: p0.0001) and rescue medication use (ITT and PP analyses: p<0.05), with no significant difference between treatments. Both treatments significantly improved overall AQLQ(S) score (ITT and PP analyses: p<0.05). Significantly more patients experienced candidiasis and dysphonia with FP compared with ciclesonide (p=0.0023).
CONCLUSION: Ciclesonide 320 microg and FP 330 microg administered twice daily over 6 months provided similar efficacy in patients with moderate or severe persistent asthma previously well-controlled by high doses of ICS at baseline. Ciclesonide was associated with fewer local AEs than FP.
Authors:
E D Bateman; A E Linnhof; L Homik; U Freudensprung; L Smau; R Engelstätter
Related Documents :
11133794 - Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, plac...
11843764 - Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to se...
2205414 - Recurrent pericarditis. relief with colchicine.
20542324 - Oral peanut immunotherapy in children with peanut anaphylaxis.
23103594 - Reno-protective effects of epigallocatechingallate in a small piglet model of extracorp...
24011814 - Comparison of graft patency, limb salvage, and antithrombotic therapy between prostheti...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2007-05-21
Journal Detail:
Title:  Pulmonary pharmacology & therapeutics     Volume:  21     ISSN:  1094-5539     ISO Abbreviation:  Pulm Pharmacol Ther     Publication Date:  2008  
Date Detail:
Created Date:  2008-03-05     Completed Date:  2008-08-01     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  9715279     Medline TA:  Pulm Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  264-75     Citation Subset:  IM    
Affiliation:
Division of Pulmonology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, PO Box 34560, Groote Schuur 7937, Cape Town, South Africa. Eric.Bateman@uct.ac.za
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Adolescent
Adult
Aged
Androstadienes / administration & dosage,  adverse effects,  therapeutic use*
Asthma / drug therapy*,  physiopathology
Bronchodilator Agents / administration & dosage,  adverse effects,  therapeutic use*
Child
Drug Administration Schedule
Female
Forced Expiratory Volume / drug effects
Humans
Male
Middle Aged
Pregnenediones / administration & dosage,  adverse effects,  therapeutic use*
Quality of Life
Recurrence
Treatment Outcome
Chemical
Reg. No./Substance:
0/Androstadienes; 0/Bronchodilator Agents; 0/Pregnenediones; CUT2W21N7U/fluticasone; S59502J185/ciclesonide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Use of a solid mixture containing diethylenetriamine/nitric oxide (DETANO) to liberate nitric oxide ...
Next Document:  Age-related bone mineral density, bone loss rate, prevalence of osteoporosis, and reference database...